Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR

被引：0
|
作者：
Carmen M. Labandeira
Maria G. Alonso Losada
Rosa Yáñez Baña
Maria I. Cimas Hernando
Iria Cabo López
Jose M. Paz González
Maria J. Gonzalez Palmás
Cristina Martínez Miró
Diego Santos García
机构：
[1] CHUVI,Department of Clinical Neurology
[2] Complejo Hospitalario Universitario de Vigo,undefined
[3] CHUO,undefined
[4] Complejo Hospitalario Universitario de Ourense,undefined
[5] Hospital de Povisa,undefined
[6] CHOP,undefined
[7] Complejo Hospitalario Universitario de Pontevedra,undefined
[8] CHUAC,undefined
[9] Complejo Hospitalario Universitario de A Coruña,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Safinamide; Non-motor symptoms; Parkinson’s disease; Depression; Mood;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5398 / 5411
页数：13
相关论文
共 50 条
  • [31] Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study
    Altman, Robert D.
    Lang, Anthony E.
    Postuma, Ronald B.
    MOVEMENT DISORDERS, 2011, 26 (13) : 2427 - 2431
  • [32] An open-label pilot study with high-dose thiamine in Parkinson's disease
    Antonio Costantini
    Roberto Fancellu
    Neural Regeneration Research, 2016, (03) : 406 - 407
  • [33] PSILOCYBIN THERAPY FOR DEPRESSION AND ANXIETY IN PARKINSON'S DISEASE: AN OPEN-LABEL PILOT STUDY
    Bradley, Ellen
    Sakai, Kimberly
    Fernandes-Osterhold, Gisele
    Szigeti, Balazs
    Ludwig, Connie
    Ostrem, Jill
    Tanner, Caroline
    Bock, Meredith
    Llerena, Katiah
    Finley, Patrick
    O'Donovan, Aoife
    Zuzuarregui, Jose Rafael
    Busby, Zachary
    McKernan, Amber
    Penn, Andrew
    Wang, Aliss
    Rosen, Raymond
    Woolley, Joshua
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 : 407 - 408
  • [34] Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open-label study
    Marsh, L.
    Bassett, S. S.
    Biglan, K.
    Gerstenhaber, M.
    Williams, J. R.
    MOVEMENT DISORDERS, 2007, 22 (12) : I - II
  • [35] Open-Label Conversion Study of Pramipexole to Ropinirole Prolonged Release in Parkinson's Disease
    Lyons, Kelly E.
    Pahwa, Rajesh
    MOVEMENT DISORDERS, 2009, 24 (14) : 2121 - 2127
  • [36] One-year open-label study of entacapone in patients with advanced Parkinson disease
    Ahn, Tae-Beom
    Im, Joo-Hyuk
    Lee, Myoung Chong
    Vim, Jae Woo
    Lee, Won Yong
    Jeon, Beom S.
    JOURNAL OF CLINICAL NEUROLOGY, 2007, 3 (02): : 82 - 85
  • [37] Effects of rasagiline on freezing of gait in Parkinson's disease - an open-label, multicenter study
    Cibulcik, Frantisek
    Benetin, Jan
    Kurca, Egon
    Grofik, Milan
    Dvorak, Miloslav
    Richter, Denis
    Donath, Vladimir
    Kothaj, Jan
    Minar, Michal
    Valkovic, Peter
    BIOMEDICAL PAPERS-OLOMOUC, 2016, 160 (04): : 549 - 552
  • [38] An open-label pilot study with high-dose thiamine in Parkinson's disease
    Costantini, Antonio
    Fancellu, Roberto
    NEURAL REGENERATION RESEARCH, 2016, 11 (03) : 406 - 407
  • [39] Istradefylline improves daytime sleepiness in patients with Parkinson's disease: An open-label, 3-month study
    Suzuki, Keisuke
    Miyamoto, Masayuki
    Miyamoto, Tomoyuki
    Uchiyama, Tomoyuki
    Watanabe, Yuka
    Suzuki, Shiho
    Kadowaki, Taro
    Fujita, Hiroaki
    Matsubara, Takeo
    Sakuramoto, Hirotaka
    Hirata, Koichi
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 380 : 230 - 233
  • [40] Evaluation of open-label rotigotine treatment in advanced Parkinson's disease
    Lyons, Kelly E.
    Pahwa, Rajesh
    Boroojerdi, Babek
    NEUROLOGY, 2008, 70 (11) : A59 - A59
12345